Panzinorm forte 20000,30 pcs.

The drug compensates insufficiency of external secretory function of the pancreas. It is a combined preparation, the action of which is caused by its components.

High lipase activity plays an important role in treatment of maldigestion caused by pancreatic enzyme insufficiency. Lipase breaks down fats by hydrolysis into fatty acids and glycerol, thus promoting their absorption and the absorption of fat-soluble vitamins. Amylase splits carbohydrates into dextrins and sugars, while protease splits proteins. It has a protective coating, due to which active enzymes are released in the small intestine, where pancreatic enzymes act.

Included in pancreatin enzymes lipase, amylase and protease facilitate the digestion of fats, carbohydrates and proteins, which contributes to their more complete absorption in the small intestine.

Moves symptoms caused by poor digestion (a heavy and full stomach, flatulence, shortness of breath, shortness of breath caused by accumulated gas in the intestines and diarrhea). Improves the process of digestion in children; stimulates the release of their own enzymes of the pancreas, stomach and small intestine and bile.

Indications

Inadequate external pancreatic secretory function (chronic pancreatitis, cystic fibrosis, etc.).

Chronic inflammatory-dystrophic diseases of the stomach, intestines, liver, gall bladder; conditions after resection or irradiation of these organs, accompanied by disorders of digestion, flatulence, diarrhea (in combination therapy).

To improve digestion in patients with normal gastro-intestinal tract function in cases of poor nutrition, disorders of masticatory function (damage to teeth and gums, while getting used to dentures), sedentary lifestyle; prolonged immobilization.

Preparing for radiological and ultrasonic examination of the abdominal cavity.

Active ingredient

Composition

1 tablet contains:

Core:

Active ingredient:

Pancreatin (porcine) (with enzyme activity:

Lipase 20,000 U.E.Pharm.,

amylase 12,000 U.E.Pharm. and drotease 900 U.E.Pharm.) 269.12 mg- 279.44 mg (15% excess pancreatin is due to technical losses in the manufacturing process. The 10% excess pancreatin is used to compensate for decay losses during the storage period).

Auxiliaries:

Lactose monohydrate,

Microcrystalline cellulose,

crospovidone,

colloidal silicon dioxide,

anhydrous,

magnesium stearate.

Shell:

Hypromellose, methacrylic acid and ethyl acrylate copolymer, triethyl citrate, titanium dioxide (E171), talc, simethicone emulsion, vanilla flavor 54286 C, bergamot flavor 54253 T, macrogol 6000, sodium carmellose, polysorbate 80.

How to take, the dosage

To be taken orally, with meals. Tablets should be taken without chewing with plenty of liquid.

The dose and duration of therapy is determined individually depending on age and degree of pancreatic insufficiency.
In adults Panzinorm forte 20,000 is recommended (in the absence of other prescriptions) at the beginning of treatment, 1 tablet 3 times a day, with each main meal.

Panzinorm forte 20,000 may be taken with a light snack. If necessary, the single dose is increased by 2 times. Average daily dose: 1-2 tablets 3 times. Before X-ray and ultrasound investigation: 2 tablets 2-3 times a day 2-3 days before the examination.

In children the drug is used by prescription. In children over the age of 3 years – 100 thousand units/day (in terms of lipase).

The duration of treatment can vary from a single dose or a few days (when digestion is disturbed due to errors in the diet) to several months or years (if permanent replacement therapy is necessary).

Interaction

Concomitant use with pancreatin may decrease absorption of iron preparations (clinically insignificant) and folic acid.

Periodic monitoring of folate levels and/or administration of folic acid is recommended. The acid-resistant coating of Panzinorm forte 20,000 tablets dissolves in the 12 duodenum.

In low pH values in the 12 duodenum pancreatin is not released. Simultaneous use of H2-histamine receptor blockers (cimetidine), hydrocarbonates, proton pump inhibitors may lead to increased effectiveness of pancreatin.

Special Instructions

Panzinorm forte 20,000 should be taken without chewing, with plenty of fluid.

In cystic fibrosis, if the necessary dose of pancreatin is exceeded (more than 10,000 units of Ph. Eur. lipase per 1 kg body weight), strictures (fibrous colonopathy) may develop in the ileocecal region and in the ascending colon. Therefore, in cystic fibrosis, the dose should be adequate to the amount of enzymes required for fat absorption, taking into account the quality and quantity of food consumed. Do not swallow the capsule of the hydrosorbent!

Impact on the ability to drive and other mechanical means: no known adverse effects on the ability to drive and operate other mechanisms.

Contraindications

With caution: pregnancy.

Side effects

In the digestive system (with prolonged use in high doses): nausea, vomiting, abdominal pain (including colic), diarrhea, constipation, perianal irritation, irritation of the oral mucosa.

In cystic fibrosis, if the required pancreatin dose is exceeded (more than 10 000 units of Ph. Eur. lipase per 1 kg body weight) strictures (fibrous colonopathy) may develop in the ileocecal region and in the ascending colon.

Allergic reactions: skin hyperemia, skin rash, skin itching, sneezing, choking, lacrimation.

Others: hyperuricemia, hyperuricosuria, folate deficiency.

Overdose

Symptoms: nausea, vomiting, diarrhea, hyperuricosuria, hyperuricemia, perianal irritation, fibrous colonopathy (in mucoviscidosis).

Treatment: drug withdrawal, hydration, symptomatic therapy.

Pregnancy use

Panzinorm forte 20,000 during pregnancy and lactation (breastfeeding) can be used only if the expected positive effect of therapy exceeds the possible risk due to the lack of clinical data confirming the safety of pancreatic enzymes in this category of patients.

Similarities